Clinical Trials Browser

Recruiting × OTHER × aumolertinib × Clear all

NCT06951464 2025-07-23

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06947811 2025-06-04

APEAK

Phase 1/2 Recruiting

EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2 Recruiting

Rare Tumor

NCT06604689 2024-11-12

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

Carcinoma, Non-Small-Cell Lung

NCT06102928 2023-10-26

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Phase NA Recruiting

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

NCT06043973 2023-09-21

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Phase 3 Recruiting

Advanced Non-small Cell Lung Cancer

NCT05800223 2023-04-05

Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer

Phase 3 Recruiting

Non-small Cell Lung Cancer Metastatic

NCT05768490 2023-03-14

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Phase 3 Recruiting

Brain Neoplasms